Russell Investments Group Ltd. Has $1.41 Million Holdings in Oxford Immunotec Global PLC (OXFD)

Russell Investments Group Ltd. lowered its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 10.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 86,855 shares of the company’s stock after selling 10,590 shares during the quarter. Russell Investments Group Ltd.’s holdings in Oxford Immunotec Global were worth $1,409,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Northern Trust Corp increased its stake in shares of Oxford Immunotec Global by 3.1% in the second quarter. Northern Trust Corp now owns 265,487 shares of the company’s stock valued at $3,423,000 after purchasing an additional 7,862 shares during the period. Renaissance Technologies LLC increased its stake in shares of Oxford Immunotec Global by 84.7% in the second quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock valued at $271,000 after purchasing an additional 9,658 shares during the period. Bank of Montreal Can acquired a new stake in shares of Oxford Immunotec Global in the second quarter valued at approximately $132,000. Rhumbline Advisers increased its stake in shares of Oxford Immunotec Global by 45.8% in the second quarter. Rhumbline Advisers now owns 32,861 shares of the company’s stock valued at $424,000 after purchasing an additional 10,320 shares during the period. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Oxford Immunotec Global in the second quarter valued at approximately $140,000. Institutional investors own 90.94% of the company’s stock.

In related news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $15.50, for a total transaction of $46,500.00. Following the transaction, the director now owns 9,000 shares in the company, valued at $139,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Peter Wrighton-Smith sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 2nd. The shares were sold at an average price of $16.71, for a total transaction of $334,200.00. The disclosure for this sale can be found here. Insiders have sold 109,100 shares of company stock worth $1,966,662 in the last quarter. Company insiders own 6.61% of the company’s stock.

NASDAQ OXFD opened at $14.98 on Friday. Oxford Immunotec Global PLC has a 12 month low of $10.00 and a 12 month high of $19.19.

Oxford Immunotec Global (NASDAQ:OXFD) last posted its quarterly earnings data on Friday, November 9th. The company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.14). Oxford Immunotec Global had a negative net margin of 12.51% and a negative return on equity of 41.15%. The company had revenue of $16.10 million for the quarter, compared to analyst estimates of $33.60 million. During the same quarter in the prior year, the business earned ($0.70) EPS. Oxford Immunotec Global’s revenue was up 7.3% compared to the same quarter last year. On average, equities research analysts expect that Oxford Immunotec Global PLC will post -1.09 earnings per share for the current year.

Several equities research analysts have commented on OXFD shares. ValuEngine upgraded shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating in a research note on Wednesday, September 12th. Piper Jaffray Companies restated an “overweight” rating on shares of Oxford Immunotec Global in a research note on Sunday, November 11th. Finally, BidaskClub upgraded shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Thursday, October 18th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Oxford Immunotec Global has an average rating of “Buy” and a consensus price target of $16.67.

TRADEMARK VIOLATION WARNING: “Russell Investments Group Ltd. Has $1.41 Million Holdings in Oxford Immunotec Global PLC (OXFD)” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/12/08/russell-investments-group-ltd-has-1-41-million-holdings-in-oxford-immunotec-global-plc-oxfd.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Featured Article: Dollar Cost Averaging

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply